**Fund of the Week: manager of the UK’s top healthcare trust on how it beat FTSE by 220%**
Healthcare investors have had a disastrous time of late.
Over the past five years, the average biotech and healthcare investment trust has fallen 13pc, losing money during a period in which the [FTSE 100 and S&P 500 hit record highs.](https://www.telegraph.co.uk/money/investing/ftse-100-record-highs-london-stock-market-dying/)
However, in Polar Capital Global Healthcare trust, investors will find an extreme outlier – over the same period, the vehicle has offered a total return of 60pc.
Its manager, Gareth Powell, sits down with Telegraph Money to explain what has worked for the team and why it will continue to grow.
He discusses the difficulties the new American health secretary will bring for the sector, and explores why his team is looking beyond incumbents [Novo Nordisk](https://www.telegraph.co.uk/business/2024/12/20/ozempic-makers-shares-plunge-after-failed-weight-loss-trial/) and [Eli Lilly](https://www.telegraph.co.uk/money/investing/stocks-shares/eli-lilly-roche-pharmaceutical-stocks-peter-rutter/) for the next generation of weight-loss drugs.
Polar Capital Global Healthcare, which is co-managed by James Douglas, currently trades at a 3pc discount to its assets.
*Fund Of The Week quizzes fund managers about how they’re investing your money. If you’d like to suggest which funds you want to hear about and pitch your questions to the managers, sign up to the Investor Newsletter* [*here*](https://secure.telegraph.co.uk/customer/secure/newsletter/investor/) *for more details.*
[https://www.telegraph.co.uk/money/investing/funds/made-434pc-one-stock-hunting-next-ozempic/](https://www.telegraph.co.uk/money/investing/funds/made-434pc-one-stock-hunting-next-ozempic/)
